Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

AACR 2024 | TAPUR: commercially available targeted therapies in solid tumors

Deepti Behl • 9 Apr 2024
AACR 2024
General
TAPUR

Deepti Behl, MD, Sutter Sacramento Medical Center, Sacramento, CA, gives an overview of the Phase II Targeted Agent and Profiling Utilization Registry (TAPUR) basket study (NCT02693535), which aims to evaluate commercially available targeted agents in solid tumors. There are many cohorts being assessed, with AKT1/3-mutated tumors making up one cohort. This interview took place at American Association for Cancer Research (AACR) Annual Meeting 2024 in San Diego, CA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Deepti Behl

1:03
The benefits of liquid biopsies for lung cancer in the community setting
Deepti Behl • 9 Apr 2024
1:33
Treating AKT1/3-mutated solid tumors with temsirolimus in the TAPUR trial
Deepti Behl • 9 Apr 2024

Related Videos

2:03
Biomarker detection for early cancer detection
Robert Rintoul • 19 Apr 2024
0:29
Innovative ctDNA-based liquid biopsy techniques for cancer diagnosis
Alain Thierry • 9 Apr 2024
0:50
Employing fragmentomics as a novel strategy to characterize and detect cancers
Alain Thierry • 9 Apr 2024
1:27
Emerging trials in melanoma: SWOG S1801, OpACIN-neo and PRADO
Christoffer Gebhardt • 9 Apr 2024
The content of VJOncology is intended for healthcare professionals